Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Exocrine Pancreatic Insufficiency: later-stage trial registry
4 of 8 indexed Exocrine Pancreatic Insufficiency trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Exocrine Pancreatic Insufficiency: 8 US clinical trials tracked, 4 recruiting.
Exocrine Pancreatic Insufficiency is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Anthera Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition exocrine-pancreatic-insufficiency
OPEN 4 | RECR 50% | LATE 6 | EARLY 0 | RANK #2176 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Exocrine Pancreatic Insufficiency lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Exocrine Pancreatic Insufficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Exocrine Pancreatic Insufficiency is recruiting above its size-band peers.
4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Exocrine Pancreatic Insufficiency research.
Anthera Pharmaceuticals accounts for 3 of 8 trials (37.5%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Exocrine Pancreatic Insufficiency trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Exocrine Pancreatic Insufficiency research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
Shwachman-Diamond Syndrome Alliance
NCT06999954
THE Malabsorption Blood Test Trial Will Help Determine THE Benefits OF Pancreatic Enzyme Replacement Therapy IN Patients With Mild TO Moderate Exocrine Pancreatic Insufficiency.
Anna Evans Phillips
NCT07418593
Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency
Ohio State University
NCT06477159
Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure
Inova Health Care Services
NCT05710315
Open-Label Phase III Long-Term Safety Trial of Liprotamase
Anthera Pharmaceuticals
NCT00449904
Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Anthera Pharmaceuticals
NCT00449878
PR-018: An Open-Label, Safety Extension of Study PR-011
Forest Laboratories
NCT01131507
SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
Anthera Pharmaceuticals
NCT02734810
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Exocrine Pancreatic Insufficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Exocrine Pancreatic Insufficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Exocrine Pancreatic Insufficiency page
8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Exocrine Pancreatic Insufficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Anthera Pharmaceuticals sponsors the most Exocrine Pancreatic Insufficiency trials on record, review their full trial history before evaluating a specific study. See Anthera Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Exocrine Pancreatic Insufficiency condition card totals 8 registered trials; most-linked intervention Liprotamase; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.